MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
Status:
Suspended
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
1. To determine the maximum tolerated dose (MTD) and the recommended Phase II dose(s) and
schedule of MSX-122
2. To characterize the dose limiting toxicities (DLTs) and determine the overall safety and
tolerability of MSX-122
Secondary Objectives:
1. To determine the pharmacokinetics and pharmacodynamics of orally administered MSX-122
2. To evaluate the preliminary evidence for anti-tumor activity of MSX-122
3. To perform correlative studies to elucidate signaling pathways involved in CXCR4
activation in blood and optional tissue specimens by IHC (immunohistochemistry) and RPPA
(reverse phase protein microarrays)